Major Shareholder GC Corp. Boosts Stake with $16.5M Purchase at Premium Price
ARTV has more than doubled off its 52-week low of $1.47.
Summary
Major shareholder GC Corp. and its subsidiary purchased $16.5 million in Artiva Biotherapeutics stock at a premium to the current market price, significantly increasing their beneficial ownership to 12.3%.
Key Events · Ownership and Investor Activity · ARTV
-
Major Shareholder Increases Stake
GC Corp. and GC Cell Corporation, along with CEO Yong-Jun Huh, collectively increased their beneficial ownership in Artiva Biotherapeutics.
-
$16.5 Million Investment at Premium
The entities purchased 1,432,291 shares for an aggregate of $16,499,992.32 at a price of $11.52 per share, which is a significant premium to the current stock price of $8.25.
-
Participation in Underwritten Offering
This purchase was made on May 11, 2026, as part of the company's recent underwritten public offering.
-
Updated Beneficial Ownership
GC Corp. now beneficially owns 12.3% of the common stock, while GC Cell Corporation owns 3.3%, reflecting a substantial commitment from these key investors.
Analysis · ARTV · Life Sciences
GC Corp., a significant 10% owner, along with its subsidiary GC Cell Corporation, has substantially increased its stake in Artiva Biotherapeutics by purchasing $16.5 million worth of common stock. This investment was made at $11.52 per share as part of the company's recent underwritten offering, which is a notable premium to the current market price of $8.25. This strong vote of confidence from a major corporate shareholder, especially at a higher price point, signals conviction in the company's future following its recent positive clinical data and capital raise.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 40.1% of the 367 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARTV was trading at $8.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $188.1M. The 52-week trading range was $1.47 to $14.53. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.